Generic Product News

Published Online: Monday, August 4, 2014
Follow Pharmacy_Times:

Azelastine HCl Nasal Solution, 0.15%

Marketed by: Perrigo Company Plc and Impax Laboratories, Inc
Compare to: Astepro Nasal Spray (Meda Pharmaceuticals, Inc)
Indication: Perrigo Company plc has announced that it has received FDA approval of its Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal solution, 0.15%. The ANDA involved contributions from Perrigo and Impax Laboratories, Inc, which will share certain costs and benefits of this product. It is indicated for the relief of symptoms of seasonal and perennial allergic rhinitis in patients 12 years and older.
Dosage Form: Nasal spray: 0.15%
For More Information: www.perrigo.com



Mimvey Lo
Manufactured by: Teva Pharmaceuticals
Compare to: Activella Tablets (Novo Nordisk Femcare)
Indication: Teva Pharmaceuticals has announced the introduction and availability of Mimvey Lo, an AB-rated bioequivalent to Novo Nordisk’s Activella Tablets. The tablets contain estradiol 0.5 mg and norethindrone acetate 0.1 mg. They are indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as the prevention of postmenopausal osteoporosis, in women who have a uterus. When prescribed solely for postmenopausal osteoporosis, therapy should only be considered for women at significant risk, and nonestrogen medications should be considered.
Dosage Form: Tablets: 0.5 mg/0.1 mg
For More Information: www.tevagenerics.com



Valsartan Tablets
Manufactured by: Ohm Laboratories, Inc
Compare to: Diovan (Novartis)
Indication: Ohm Laboratories, Inc, a wholly owned subsidiary of Ranbaxy Laboratories, Limited, announced today that Ohm has received FDA approval to manufacture and market Valsartan 40-, 80-, 160-, and 320-mg tablets on an exclusive basis. Valsartan is the generic version of Novartis’ Diovan. It is indicated for the treatment of high blood pressure and heart failure.
Dosage Form: Tablets: 40, 80, 160, and 320 mg
For More Information: www.ranbaxy.com



Cyclophosphamide Capsules
Manufactured by: Roxane Laboratories
Compare to: Cyclophosphamide tablets (Roxane Laboratories)
Indication: As of June 2014, Roxane Laboratories began providing cyclophosphamide in capsules, an FDAapproved, clinically equivalent version of its discontinued cyclophosphamide tablets. The tablets are indicated for the treatment of malignant lymphomas including Hodgkin’s disease and lymphocytic lymphoma, and minimal change nephrotic syndrome in pediatric patients who fail to respond to adrenocorticosteroid therapy. The new capsules are not automatically substitutable for tablets, so pharmacists should verify that scripts specify capsules in addition to the dosage.
Dosage Form: Capsules: 25 and 50 mg
For More Information: www.roxane.com




Related Articles
The JNC 8 guidelines are based on 27 large clinical trials that are often discussed in isolation, but have never been aggregated into a single source until now.
Joseph Saseen talks about a few things pharmacists should consider with patients who have uncontrolled hypertension and who are taking multiple medications.
Joseph Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS, professor in the Departments of Clinical Pharmacy and Family Medicine at University of Colorado Skaggs School of Pharmacy, talks about the new knowledge surrounding hypertension that we have learned in the past 5 to 10 years.
Joseph Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS, professor in the Departments of Clinical Pharmacy and Family Medicine at University of Colorado Skaggs School of Pharmacy, talks about the role age plays in deciding blood pressure goals.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$